Abstract. The treatment of glioblastoma is unsatisfactory.
Introduction
Glioblastoma is the most common primary brain tumor and the prognosis for a patient diagnosed with this disease is still poor. However, the outcome has increased significantly by modern multimodal treatment, consisting of surgery, radiochemotherapy and adjuvant chemotherapy, leading to a median survival of 16 months and a 2-year survival of almost 30% (1) . Due to its infiltrative growth, glioblastoma may be considered a generalized central nervous system disease and therefore new systemic treatments are necessary to improve treatment outcome.
Neovascularisation is commonly regarded as one of the hallmarks of cancer (2) . Extensive angiogenesis is associated with worse prognosis in glioblastoma (3, 4) and vascular endothelial growth factor (VEGF) is reported to be one of the key positive regulators of angiogenesis in brain tumors (5, 6) . Different strategies for anti-angiogenesis treatment have shown promise in the experimental setting for malignant glioma (7) . These include antisense-VEGF strategies (8) , anti-VEGF monoclonal antibodies (9) , anti-VEGF-receptor (VEGFR) monoclonal antibodies (10) , soluble VEGF decoy receptors (11) , and small molecule VEGFR tyrosine kinase inhibitors (12) (13) (14) (15) . Recent phase II clinical data indicate that the anti-VEGF monoclonal antibody bevacizumab is also active in human glioblastoma (16) (17) (18) .
Vandetanib (ZD6474) is a small molecule inhibitor of the tyrosine kinase of VEGFR2, VEGFR3 and epidermal growth factor receptor (EGFR) (19) . Vandetanib has shown promising effects on tumor growth in a panel of subcutaneous tumor models (20) as well as in an intracranial rat glioma model (13) . The molecule is now in clinical trials for various tumors, including glioma. This compound has recently shown interesting combination effects when given together with radiotherapy or temozolomide in an orthotopic rat glioma model (21) . Due to its dual action as an inhibitor of angiogenesis as well as EGFR driven tumor cell proliferation, it is an interesting compound for glioma treatment.
One clinical problem in the evaluation of new systemic treatments for cancer in general and brain tumors in particular is the need for new ways to predict treatment response. Present treatment regimens have usually been evaluated using conventional radiological methods several months after treatment initiation. The development of new biological and radiological methods for detection of early treatment response is of great importance when an increasing number of new signal transduction inhibitors are to be evaluated. One step in this direction is to investigate the effect of a given treatment based on the protein expression pattern. With respect to glioma treatment this has previously been performed in cell culture systems (22, 23) . In the present study, the pattern of protein expression in an experimental in vivo glioma model following treatment with the angiogenesis inhibitor vandetanib was evaluated, using surface enhanced laser desorption/ ionization time of flight mass spectrometry (SELDI-TOF-MS).
Materials and methods
Animal model. The BT4C syngenic intracerebral rat glioma model was used for the in vivo experiments in this study (24, 25) . The BT4C rat glioma cells were grown in Dulbecco's modification of Eagle's MEM (DMEM) (Gibco/Invitrogen Corp., Paisley, Scotland, UK) supplied with 5% BD-IX fetal calf serum. When grown in log-phase the cells were harvested and diluted to a concentration of 4,000 cells/μl. A 22G microsyringe (Unimetrics, Shorewood, IL) fitted to a stereotactic frame was used to inject 5 μl of the cell suspension into the right caudate nucleus of the inbred BD IX rats. Care was taken to prevent reflux in the insertion canal and burr hole by a slow injection and the use of bone wax. During the implantation procedure, cells were kept on ice and the viability was monitored by intermittent tryphan-blue staining. The rats were anaesthetized with a 1:1 mixture of Hypnorm ® (fluanisone 10 mg/ml and fentanyl citrate 0.315 mg/ml) and Dormicum ® (midazolam 5 mg/ml) in the dose 0.5 ml/100 g. In addition, local anaesthesia (Xylocain ® 10 mg/ml) was used in the scalp. The animals were provided with food and water ad libitum and were housed in a controlled environment with 12-h light/dark cycles. An experienced animal keeper supervised the care of the animals.
Treatment. In total, 27 animals were used. The animals were divided into three experiments with different times of initiation and duration of treatment (Fig. 1) . The first two experiments each consisted of four rats receiving treatment, daily oral dosages of 50 mg/kg vandetanib, and three untreated control animals, respectively. Treatment for both these experiments commenced on day 6 after implantation and lasted for 6 and 14 days in experiment 1 and 2 respectively. Hence all animals in experiment 1 were sacrificed on day 12 after implantation and all animals in experiment 2 on day 20 after implantation. All 9 animals in the third experiment were treated with a single dose of 50 mg/kg vandetanib on day 19 after implantation and then sacrificed in groups of three; 2, 8, and 24 h after treatment. To save animals, the untreated animals from experiment 3 served as a control group also for this experiment. In addition, 4 tumor-free, sham-operated animals were included in the study. These animals were subject to the same surgical procedure as all the other animals, except that saline was injected instead of tumor cells.
After decapitation, tumors were grossly dissected together with contralateral normal brain tissue. Tissue was snap-frozen in liquid nitrogen and stored at -80˚C. The experiment was approved by the Umeå University ethics committee for animal research.
Vandetanib (ZD6474).
Vandetanib was kindly provided by AstraZeneca, Alderley Park, UK. For details and chemical structure see Hennequin et al (19) . Vandetanib was dissolved according to the manufacturer's instructions in 1% Tween-80 (Merck-Schuchardt, Hohenbrunn, Germany) to a concentration of 10 mg/ml. Glass beads were added to the mixture to obtain a uniform suspension. The suspension was then milled overnight at room temperature.
Tissue preparation. To allow for protein profiling analyses, each tissue sample was homogenized in a series of steps. The sequence in which the samples were handled was randomized to avoid systematic differences as a result of sample treatment. Each sample was firstly thoroughly homogenized in 1 ml homogenization buffer 1 (100 mM HEPES, pH 7.4, 100 mM NaCl, 0.5% CHAPS) per 100 mg tissue, with a Dounce Tissue Grinder (Kimble/Kontes, Vineland, NJ, USA), and then incubated on ice for 30 min. Thereafter, the homogenate was centrifuged at 20,800 g for 20 min at 4˚C and both the supernatant and the pellet fraction were recovered. The supernatant was dissolved in two volumes of protein denaturing buffer (8 M urea, 1% CHAPS, PBS), kept on a shaker for 30 min at 4˚C and then snap-frozen in liquid nitrogen and stored at -80˚C. The pellet fraction was transferred back to the tissue grinder and rehomogenized in 1 ml homogenization buffer 2 [5 M Guanidine-HCl, 50 mM Tris (pH 8.0), 0.5% CHAPS] per 100 mg tissue, then incubated on ice for 3 h, followed by centrifugation at 20,800 g for 20 min at 4˚C before it was snap-frozen in liquid nitrogen and stored at -80˚C. Both homogenization buffers contained Complete EDTAfree Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN, USA). The protein concentration of each sample was measured using the bicinchoninic assay (BCA) (Pierce Biotechnology, Inc., Rockford, IL, USA).
Sample analysis. The protein content of each sample was profiled using SELDI-TOF-MS, and certain ProteinChip arrays (Bio-Rad Laboratories Inc., Hercules, CA, USA). The array types used were CM10 (a weak cat ion exchange surface) and IMAC (an immobilized metal affinity chromatography surface) coupled with Cu 2+ ions. The analyses were done for one fraction at a time, on one array type at the time, and the samples were applied to the protein chip arrays in triplicates according to a randomized scheme. To facilitate evaluation of analytical reproducibility a number of quality control (QC) samples were analyzed together with the other samples, randomly located to different spots on the ProteinChip arrays. The array preparation strategy has been described in detail elsewhere (26) , below follows a short description.
The IMAC arrays were charged two times with Cu 2+ ions by addition of 50 μl of 100 mM CuSO 4 for 5 min. Unbound metal ions were removed by two washes with 100 μl 1 mM HEPES for 5 min. All subsequent array preparation steps were then identical for both array types. The first of which was equilibration with 150 μl array specific binding buffer, where the binding buffers used were 0.1 M PO 4 , pH 7.5 with and without 0.5 M NaCl for the IMAC and the CM10 arrays, respectively. The equilibration step was repeated two more times. In parallel to the pre-treatment of the ProteinChip arrays, the samples were thawed on ice and diluted in binding buffer to a concentration of 150 ng/μl. One hundred μl of the diluted samples were added to the pre-treated ProteinChip arrays and allowed to incubate for one hour. All arrays were then washed three times with binding buffer for 5 min and twice with 1 mM HEPES for 1 min. Lastly, the arrays were air-dried for 15 min before addition of the energy absorbing molecule (EAM) matrix. The EAM used was 50% saturated sinapinic acid, diluted in 50% acetonitrile and 0.5% triflouroacetic acid, which was added in two deliveries of 1 μl each, 3 min apart.
The array preparation was carried out in room temperature using the Biomek 2000 Laboratory Automation Workstation robot (Beckman Coulter Inc., Fullerton, CA, USA), coupled with a MicroMix 5 shaker (Diagnostic Products Corp., Los Angeles, CA, USA), which was used for all incubations, set to program 5 and amplitude 20. The arrays were subsequently analyzed twice in the TOF mass spectrometer (PBS-II; Bio-Rad Laboratories Inc.), with different settings optimized for different mass regions; 1.8-10 and 10-20 kDa. In addition, the QC-samples were also analyzed with settings optimized for a wider mass region: 1.8-20 kDa.
Analytical reproducibility. Spectra from the QC samples were used to evaluate the analytical reproducibility, and therefore treated separately from the rest. The QC spectra were baseline subtracted and then normalized together in the ProteinChip Software v3.2.2 (Ciphergen Biosystems Inc., Fremont, CA, USA). Clusters of peaks were selected within the mass region 2.5-20 kDa, using the Biomarker Wizard tool with the following settings; first pass signal to noise ratio = 5, min peak threshold = 50% of all spectra, cluster mass window = 0.3% of mass, second pass signal to noise ratio = 2, with the noise set to be calculated within the same mass region. A coefficient of variance (CV) value was calculated for each peak cluster individually, and the mean of each peak cluster's CV was used as a measure of the reproducibility.
Data pre-processing. Following baseline subtraction, which was carried out using the ProteinChip Software, spectra from both analyzed mass regions for each sample were exported. To allow for meaningful comparison between spectra from different samples, the exported data were subject to a binning procedure, using 2.5 and 3.5 Da as bin sizes for the 1.8-10 and the 10-20 kDa regions, respectively. Each spectrum was then normalized by total ion current (TIC), i.e., each bin variable was divided by the mean of all bin variables in the mass region. Prior to multivariate data analysis the data were mean centered, and scaled by either pareto-or unit variance (UV) scaling.
Data analyses. The use of two separate sample fractions, each analyzed on two different ProteinChip array types at two different mass regions, gave rise to 8 different data subsets in total. The complete protein profiles from each subset were pre-processed and assembled into separate data tables denoted as X-matrices.
Each X-matrix was initially scanned for possible outliers, i.e., deviating samples not suitable to be included in further analysis. This was done by means of principal component analysis (PCA). Samples detected as outliers, including spectra of inadequately low quality and possibly contaminated samples, were excluded. Following PCA, the X-matrix was pareto scaled and analyzed by orthogonal partial least squares discriminant analysis (OPLS-DA) (27) versus a response matrix (Y), containing three dummy variables describing tissue type (normal or tumor), treatment and the interaction term between these two variables. This analysis resulted in three predictive OPLS-components. The correlation loading vectors [p(corr)] and the covariance loading vectors (w * ) from each component were subsequently used to define spectral regions of interest (ROI), i.e. regions where consecutive bin-variables displayed either large absolute p(corr)-values (|p(corr)| >0.5) or large absolute w * -values (|w * | >0.025). Variables within ROI that constituted local maxima (peaks) in the mean protein profile from any of the compared groups were then located, and their intensity data extracted from all individual observations. This was done by identifying local maximum intensities in each observation's profile within ±0.2% of the m/z-value defined as a peak in the mean spectrum in order to compensate for possible mass shifts. Peaks with a normalized mean intensity <1 in both groups were discarded, together with peaks displaying a resolution <100 in both groups, as calculated by Full Width at Half Maximum on the mean profile.
The procedure described above was repeated for all eight data subsets, and the extracted data from all subsets were compiled in a new X-matrix (X b ). The variables in X b were UV-scaled prior to OPLS-DA analysis against the same response matrix (Y) as described above. The p(corr)-vectors from the components describing treatment effects in normal and tumor samples, respectively, were used to locate the peaks most notably affected by treatment in any of the tissue types. Peaks with an absolute p(corr)-value > 0.5 in at least one of the vectors were considered as interesting.
In addition, a permutation analysis was employed to locate peaks affected by treatment. This was done for one tissue type at a time, where the correlation between each peaks' expression pattern (Xb) and a response variable (y), representing treatment, was calculated. The response variable was then randomly permutated, and a new correlation value was calculated. This was repeated 10,000 times, and variables with a greater correlation to the original y than any of the permuted y-variables were considered as interesting. The permutation procedure was repeated three times and the variables surviving the test at least once were included for further evaluation.
Finally, all selected peaks were confirmed by manual inspection of the spectra and validated using a Mann-Whitney Table I . Peaks significantly altered by treatment, found in the pellet fraction analysed on CM10 arrays. c N and T denote normal and tumor, respectively. d Mean normalized intensity for untreated samples. e Mean normalized intensity for treated samples.
f p-values were calculated by Mann-Whitney U statistics for each peak. g x denotes that it was found significant by permutation and -denotes that it was not.
-
U test to generate a p-value. Two final, UV-scaled OPLS-DA models were then calculated, using a single response variable (y) representing treatment; one for samples from normal tissue based on peaks displaying significant (p<0.01) treatment effects in normal tissue, and one for tumor samples based on peaks significantly affected in tumor tissue. To visualize the altered expression pattern in normal and tumor tissue respectively in a reliable fashion, cross-validated (CV) scores plots were used.
Data from each of the three experiments were analyzed separately, and for each significantly affected peak an exact mass value was extracted from the raw data. The results were complied into 4 separate tables (Tables I-IV), one for each Table II . Peaks significantly altered by treatment, found in the supernatant fraction analysed on CM10 arrays. c N and T denote normal and tumor, respectively. d Mean normalized intensity for untreated samples. e Mean normalized intensity for treated samples.
combination of sample fraction and array type. Peaks who's m/z-values were not significantly different (p<0.01) were considered to have the same m/z, and thus listed together on the same row in the result tables. For all multivariate data modeling steps described above, the cross-validation scheme was designed to keep all replicates of one sample excluded in the same CV-round. This has the effect that the presented cross-validated scores plot will present a predictive pattern, where each predicted subject can be considered as unknown to the model.
Results
Analytical reproducibility. The tissue samples in this study were initially fractionated into two fractions, they were both subsequently analyzed on two separate types of ProteinChip Table III . Peaks significantly altered by treatment, found in the pellet fraction analysed on IMAC arrays. c N and T denote normal and tumor, respectively. d Mean normalized intensity for untreated samples. e Mean normalized intensity for treated samples.
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arrays. Each fraction was analyzed on one ProteinChip array type at a time, resulting in a total of four individual runs. The achieved analytical reproducibility varied between 16.6 and 29%, as measured by means of mean CV on a number of quality control samples analyzed in every run (Table V) .
Excluded samples. The number of included samples in the various experiments was reduced following exclusion of detected outliers. From experiment 1, where the animals received treatment for 6 days, all three replicates of two tumor samples were excluded from all subsets; one treated and one untreated. From experiment 2, where the animals received treatment for 14 days, all comparisons of treated and untreated tumors were based on CM10 data alone, due to a large number of excluded tumor samples from the IMAC subsets. From the same experiment, 1 analytical replicate of an untreated tumor sample was excluded from the CM10 datasets.
From experiment 3, where the animals received a single dose vandetanib 19 days after implantation, all comparisons of treatment effects after 24 h were carried out only on data acquired on CM10 ProteinChip arrays, as a consequence of many exclusions from the IMAC datasets.
Overview of untreated samples. PCA on complete protein expression profiles (X) from untreated samples revealed a large variation between the different types of samples included in the study (Fig. 2) . Each individual sample group clustered fairly well together and there was a distinction between the tumor samples and non-tumor samples. A difference related to tumor progression could also be observed, where tumor samples from animals with tumors implanted for 12 days clustered closer the non-tumor samples than those from animals with tumors implanted for 20 days. Furthermore, a trend was detectable among the overlapping groups of nontumor samples, where samples from tumor-bearing rats clustered closer to the tumor samples as compared to the samples from sham operated, and tumor-free rats.
Effects of treatment.
An overview of the mean normalized and binned spectra of tumor samples from all experiment groups, both from treated and untreated control animals, is presented in Fig. 3 . The animals in the first experiment group, with tumors implanted for 12 days receiving daily doses of vandetanib for the last 6 days, displayed 13 peaks with a significantly altered expression (5 in normal and 8 in tumor tissue) between treated and untreated control animals (Tables I-IV) . The cross validated scores from the final, Table IV . Peaks significantly altered by treatment, found in the supernatant fraction analysed on IMAC arrays. f p-values were calculated by Mann-Whitney U statistics for each peak. g x denotes that it was found significant by permutation and -denotes that it was not. Table V . SELDI-TOF-MS analytical reproducibility. 
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UV-scaled, OPLS-DA models, based on the combined expression pattern of these peaks, displayed a clear separation of the tumor samples as a result of treatment. The equivalent separation was less evident among the normal tissue samples (Fig. 4) .
Twenty days after tumor implantation, following 14 days of treatment, 39 peaks in total were detected with a significantly altered intensity between treated and untreated animals. Ten of these peaks were common between the tissue types, 22 were specific for normal tissue samples and 7 specific for tumor samples (Tables I-IV) . The cross-validated scores from the final, UV-scaled, OPLS-DA models, based on the combined expression pattern of these peaks, displayed clear separations in both tissue types (Fig. 5) .
Furthermore, we compared protein expression in normal and tumor tissue at 3 different time-points (2, 8 and 24 h) after a single dose of vandetanib in animals with tumors implanted for 19 days (experiment 3). From these three comparisons carried out in both tissue types, a total of 40 peaks were detected showing a significantly altered intensity, after at least one of the analyzed time-points, in treated tissue as compared to untreated tissue of the same sort (tumor or normal). Nineteen of these were found specifically in tumor tissue, 17 specifically in normal tissue and 4 were found in both tissue types (Tables I-IV ). In the cross-validated scores from the final, UV-scaled, OPLS-DA models based on these peaks it was clear that each of the treated groups were different from the control group. The separation was more evident among the tumor samples than among the samples from normal tissue, where a slight overlap was seen (Fig. 6) .
Discussion
In the present study, a distinct and time-dependent alteration in the protein expression pattern of malignant glioma and normal brain is reported after vandetanib treatment, as examined by a mass-spectrometric method and multivariate data analysis. A list of peaks significantly affected by treatment is presented and may represent future candidate biomarkers for treatment response. To our knowledge, this is the first study that investigates the influence of a tyrosine kinase inhibitor on the protein expression pattern in an in vivo glioma model.
Today, there are few biological markers in clinical use for brain tumor treatment decision-making. For glioblastoma treatment, methylation of the O6-methylguanin-DNA methyltransferase (MGMT) gene, predicts a significantly better response to treatment with alkylating agents (28, 29) . In tumors of oligodendroglial origin, loss of heterozygosity (LOH) 1p and 19q appears to harbor prognostic as well as predictive information (30, 31) . These novel biomarkers are now being integrated in clinical trials and everyday clinical practice. However, in the search for new glioblastoma treatments, specific and reliable markers for early treatment response are urgently needed. This is accentuated when it comes to the development of anti-angiogenesis treatments, aiming to inhibit tumor vascularisation. Here, traditional indicators of response, such as radiological tumor size evaluations, are not per se indicators of successful inhibition of angiogenesis. At present, there are no reliable markers of response to anti-angiogenesis treatment, but a few candidates have been proposed. In the experimental situation, micro-vascular density (MVD) has been used to assess effects of anti-angiogenesis treatment, though this usage is disputed (32) . Another suggested measure of anti-angiogenesis treatment effects is by assessment of the number of circulating endothelial cells (CEC) and circulating endothelial progenitor cells (CEP) (33, 34) . The usefulness of these tools was further evaluated by Beaudry et al, who describe differential changes in the levels of CEC and CEP following treatment with vandetanib (35), the same tyrosine kinase inhibitor that was used in the present study. Moreover, MRI based radiological methods for imaging of the tumor vascular compartment have been reported to add predictive information for anti-angiogenesis treatment (36, 37) . These MRI methods are promising and have the advantage of being non-invasive. Even though changes in CEC/CEP levels or MRI perfusion parameters may reflect successful angiogenesis inhibition per se they are less likely to be specific for a particular angio-genesis inhibitor.
Proteomic protocols are attractive methods to find new biomarkers. The biological and physiological effects of antiangiogenesis treatment are several, including inhibition of endothelial cell proliferation and functional normalization of the tumor vascular bed (7, 20, 38) . Biomarkers for anti- angiogenesis treatment may therefore be found in different cell-signaling pathways directly or indirectly affected by a specific treatment. A proteomic screening approach, employing a method such as SELDI-TOF-MS, then holds the potential to discover novel protein markers as well as expression patterns of interest. The capacity of this method to analyze samples from cancer patients has been established previously (39, 40) . It has also been utilized to detect treatment-induced changes in the urinary proteome of patients with polycystic kidney diseases (41) as well as by our group for studying effects of radiotherapy in rat glioma (26) . However, most previous studies on treatment-induced changes in glioma protein expression patterns have been performed in vitro (22, 23, 42) . in vivo, however, tumor cells are in continuous interaction with stromal cells (43) , which will impact on the tumor cells' protein expression pattern. Therefore, in the search for biomarkers we believe that it is important to study treatment effects in vivo.
Application of multivariate analysis methods was essential to efficiently handle the large amounts of information generated. We also believe this approach opens for the possibility to find panels of markers displaying specific patterns of expression that may be indicative of a specific biological state, even when none of the markers individually would be. When working with supervised data analysis methods, such as OPLS-DA, there is an inherent risk of generating false-positive findings due to overestimation of the data. In this study we have minimized this risk by use of extensive validation, including cross-validation, response permutation and Mann-Whitney statistics. Essentially, the data analysis was divided into two separate parts; initial analysis of complete expression profiles, carried out individually for each data subset, followed by analysis of selected peaks from all subsets (Xb). For the second step, two complementary approaches were used; investigation of OPLS-DA loadings and permutation analysis. The two approaches complement each other in the sense that in cases when the OPLS-DA model based on the Xb-matrix failed to completely divide the treatment effects into the second two predictive components, there was a risk of missing potentially important variables by studying the p(corr)-loading vectors of these two components alone. At the same time, the permutation test is very stringent and using only this approach could lead to missing possibly important peaks.
In the present study we report a total of 78 peaks in our spectra whose intensities changed significantly following treatment with vandetanib. There is a risk that Tables I-IV, listing peaks significantly affected by treatment, may contain overlapping information, as a consequence of the possibility that the same molecule can be present in both sample fractions analyzed and that it can bind to both of the used array types. However, the peaks found to be affected by a single dose were different ones at different time-points after treatment, indicating a dynamic immediate response. Furthermore, we could detect distinct differences between protein profiles from untreated tumors at different time-points after implantation (Fig. 2) . Given that these tumor groups display different protein expression characteristics to begin with, one would expect to find discrepancies between the groups also among the treatment induced changes, which was indeed the case (Tables I-IV) . The complexity and dynamics of the protein expression is also demonstrated visually in Fig. 3 , which further stresses the importance of designing experiments including control groups for each individual time-point of interest. In many previous proteomic studies of glioma in vitro the analyses of protein expression have been done at a single time-point after treatment (22, 23, 42, 44) . Based on our findings, together with the information from the earlier referred study (26) , we believe that the issue of proteomic response in malignant glioma to treatment is complex and that potential markers may be expressed differently in relation to timing of treatment and sampling of specimens.
Our findings demonstrated distinctly different protein expression patterns in tumor tissue as the tumor progresses over time. This is in concordance with previous findings in the same animal model (26) . In the present study, the analysis has been expanded as compared to the previously published study, to include separate, thorough investigations of different durations of treatment in both tumor and contralateral normal tissue. Taken together, SELDI-TOF-MS in combination with appropriate multivariate statistical methods seem well suited for screening studies of treatment effects following various treatments and hold the potential to discover novel markers.
Interestingly, we found significant differences in the protein expression profile induced by vandetanib treatment also in normal brain. As shown in Fig. 2 , the normal tissue contralateral to the BT4C tumor seems to have a slightly different protein expression profile than normal brain tissue from tumor-free, sham-operated rats. The normal tissue from tumor-bearing rats clustered more towards the tumor samples. This may be explained by the presence of invading tumor cells or by a physiologic effect induced by the growing tumor in the contralateral hemisphere. The treatment effects observed in the normal brain of rats with BT4C tumors may be an indirect effect due to altered physiology after treatment or a direct effect on invading glioma cells. However, it cannot be excluded that the observed changes in the protein profile of normal brain, at least in part, may be a direct effect on normal brain tissue. Vandetanib has in clinical studies on pulmonary carcinoma and breast carcinoma not been reported to exert any obvious neurotoxic side-effects and only a few cases with mild headache were reported (45, 46) . Notably, the animals in this and previous series have not shown any apparent neurologic side-effects (13, 21) .
In conclusion, the present study reports a significantly altered protein expression pattern in malignant glioma and normal brain, following anti-angiogenesis treatment with the tyrosine kinase inhibitor vandetanib. A number of candidate biomarkers for treatment response were detected for further characterization. We believe that clinically relevant biomarkers for anti-angiogenesis treatment response in glioblastoma may be important in the future development of new treatment combinations.
